The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 359:766-768 August 14, 2008 Number 7
NextNext

Glucagon-like Peptide 1–Receptor Scans to Localize Occult Insulinomas

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Supplementary Material

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: The precise localization of some insulinomas (islet-cell adenomas that secrete insulin) with the use of conventional imaging techniques, such as computed tomography (CT), magnetic resonance imaging (MRI), endosonography,1 and indium-111 (111In)–labeled pentetreotide scintigraphy (OctreoScan),2 is a challenging clinical problem. In vitro studies have demonstrated that receptors for glucagon-like peptide 1 (GLP-1) are highly overexpressed in almost all insulinomas.3,4 Therefore, GLP-1-like radioligands retaining high binding affinity to GLP-1 receptors have been developed. One such radioligand, [Lys40(Ahx-DTPA-111In)NH2]exendin-4, successfully targeted insulinomas in the Rip1-Tag2 mouse.5 We evaluated the diagnostic value of GLP-1–receptor scintigraphy in two patients . . . [Full Text of this Article]


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.